

06/12/00
JCS39 U.S. PTO

06/12/00

Box 500

McGREGOR & ADLER, LLP

P.O. BOX 710509
HOUSTON, TEXAS 77271-0509

JCS39 U.S. PTO
09/591737
06/12/00

WRITER'S DIRECT DIAL
(713)-777-2321
WRITER'S DIRECT FACS
(713)-777-6908
E-MAIL: BADLER1@houston.rr.com

INTELLECTUAL PROPERTY LAW
(PATENT, BIOTECHNOLOGY, COMPUTER,
TRADEMARK & TRADE SECRET LAW)

June 12, 2000

Docket No.: D6167CIP

The Assistant Commissioner of Patents
BOX PATENT APPLICATION
Washington, DC 20231

Dear Sir:

Transmitted herewith for filing is the continuation-in-part patent application which claims benefit of priority under 35 USC §120 of USSN 09/407,511, filed September 28, 1999, now pending, which claims benefit of priority under 35 USC §119(e) of U.S. provisional application number 60/102,257, filed September 29, 1998, now abandoned, in the:

Name of: **Curiel, et al.**

For: ***Immunomodulation by Genetic Modification of Dendritic Cells and B Cells***

CLAIMS AS FILED

Fee for:	Small entity	Amount
Basic fee	\$ 345	\$ 345
Each independent claim in excess of 3 (0)		
Each claim excess of 20 (36) \$ 9		\$ 324
Multiple dependent claim		
TOTAL FILING FEE		\$ 669

the filing fee and the assignment recordation fee if any.

X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 07-1185.

X Any additional fees under 37 CFR 1.16.

X Any application processing fees under 37 CFR 1.17.

X Small Entity Statement

A small entity statement is enclosed and its benefit under 37 CFR 1.28(a) is hereby claimed.

X Relate Back--35 U.S.C. 119(e)

This continuation-in-part patent application claims benefit of priority under 35 USC §120 of USSN 09/407,511, filed September 28, 1999, now pending, which claims benefit of priority under 35 USC §119(e) of U.S. provisional application number 60/102,257, filed September 29, 1998, now abandoned.

X Sequence Listing

The sequence listing is enclosed, including a paper copy, a computer readable form and a compliance letter indicating that the sequence listing on the paper copy and the disk are one and the same.

X Power of Attorney

X is attached.

X Address all future communications to:

Benjamin Aaron Adler
McGREGOR & ADLER, LLP.
8011 Candle Lane
Houston TX 77071
(713) 777-2321
BADLER1@houston.rr.com

X Two photocopies of this sheet are enclosed.

100 100 12, 2000

Benjamin Adler

Registration No. 55,425

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Curiel, *et al.*

§

ART UNIT:

§

FILED: June 12, 2000

§

§

SERIAL NO.:

§

§

FOR: Immunomodulation by Genetic
Modification of Dendritic Cells
and B Cells

§

§

§

EXAMINER:

DOCKET:

D6167CIP

The Commissioner of Patents and Trademarks
BOX PATENT APPLICATION
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

Dear Sir:

I hereby certify that the following documents, which are attached, are being deposited, under 37 CFR 1.10, with the United States Postal Service "Express Mail Post Office to Addressee" service as Express Mail No. EL559421109US in an envelope addressed to: The Commissioner of Patents and Trademarks, BOX PATENT APPLICATION, Washington, D.C. 20231, on the date indicated below:

- 1) Continuation-in-part application + 30 sheets of drawings;
- 2) Transmittal Letter;
- 3) Two (2) Combined Declarations and Powers of Attorney;
- 4) Verified Statement of Small Entity Status;
- 5) Sequence Listing, Compliance Statement & CRF disk;
- 6) Filing fee (\$669) and return postcard.

Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

Date: June 12, 2000
McGREGOR & ADLER LLP


Benjamin Aaron Adler Ph.D. J.D.

USPTO 2021
BADLER1@houston.rr.com